Clinical trials: Hematologic
Acquired Factor X Deficiency
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
The purpose of this study is to evaluate the efficacy and safety of Coagadex in treating active bleeds and to manage peri-operative bleeding in participants with acquired factor X deficiency associated with AL amyloidosis.
- Trial name
- NCT06963216
- Testing
- Coagadex(R)
- Sponsor
- Kedrion S.p.A.
Complement Mediated Glomerular Diseases, Hemolytic Anemia
Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects
The study is being conducted to compare the drug-drug interaction of HRS-5965 with clopidogrel and clarithromycin in healthy subjects.
- Trial name
- NCT07040787
- Testing
- HRS-5965 Capsules, Clopidogrel, Clarithromycin
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Eosinophilic Esophagitis
Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis
The purpose of this study is to assess the efficacy of a low and high dose of a budesonide effervescent tablet and oral viscous budesonide suspension vs. placebo for the induction treatment of active eosinophilic esophagitis.
- Trial name
- NCT02280616
- Testing
- low dose budesonide tablet, high dose budesonide tablet, high dose budesonide suspension
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- Dr. Falk Pharma GmbH
Sickle Cell Anemia, Thalassemia
L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
The purpose of this research is to evaluate the effects of L-glutamine as a therapy for sickle cell anemia and sickle ß0-thalassemia. as evaluated by the number of occurrences of sickle cell crises.
- Trial name
- NCT00125788
- Testing
- L-glutamine
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Emmaus Medical, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body.
- Trial name
- NCT04683003
- Testing
- TAK-755
- Where
- 27 sites in United States, Austria and 9 more
- Volunteers
- 77 people
- Sponsor
- Takeda
Multiple Myeloma
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).
- Trial name
- CARTITUDE-4 (NCT04181827)
- Testing
- Cilta-cel, Pomalidomide, Bortezomib
- Where
- 88 sites in United States, Australia and 14 more
- Volunteers
- 419 people
- Sponsor
- Janssen Research & Development, LLC
Von Willebrand Disease, Type 1, Heavy Menstrual Bleeding
Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With and Without Von Willebrand Disease
The objectives of this study are to determine if transcutaneous auricular neurostimulation (tAN) can modulate hemostasis, improve perceived quality of life, and improve pain during the menstrual cycle of von Willebrand Disease…
- Trial name
- VWD/HMB (NCT06064851)
- Testing
- Volta System
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Five Liters, Inc.
Multiple Myeloma
Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma
The overarching objective of this study is to evaluate the feasibility, usability, and acceptability of an abbreviated, tablet-based geriatric assessment in a population of older adults with multiple myeloma.
- Trial name
- NCT03068637
- Testing
- Carevive CPS
- Where
- 2 sites in United States
- Volunteers
- 165 people
- Sponsor
- Carevive Systems, Inc.
Congenital Fibrinogen Deficiency, Afibrinogenemia
Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap
The purpose of this study is to investigate pharmacokinetic properties, surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P/RiaSTAPTM in patients with congenital fibrinogen deficiency
- Trial name
- NCT01575756
- Testing
- Octafibrin, Haemocomplettan® P or RiaSTAPTM
- Where
- 10 sites in United States, Bulgaria and 4 more
- Volunteers
- 22 people
- Sponsor
- Octapharma
Anemia
Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging
The primary objectives of this study to evaluate the safety, tolerability and efficacy of BGE-117 in the treatment of anemia of aging in participants ≥ 65 years of age.
- Trial name
- NCT04815603
- Testing
- BGE-117
- Where
- 13 sites in Australia
- Sponsor
- BioAge Labs, Inc.
Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory
BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, however not all tumors respond or remain in response to CD19…
- Conditions
- Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin Lymphoma, B-cell
- Trial name
- NCT07771361
- Testing
- BAFF CAR-T
- Volunteers
- 90 people
- Sponsor
- Luminary Therapeutics
Osteoporosis, Osteoarthritis
OSTEOMICS: Identifying Regulators of Bone Homeostasis
Diseases of bone associated with ageing, including osteoporosis (OP) and osteoarthritis (OA), reduce bone mass, bone strength and joint integrity.
- Conditions
- Osteoporosis, Osteoarthritis, Bone Diseases, Bone Fracture
- Trial name
- OSTEOMICS (NCT05732870)
- Testing
- Relevant orthopaedic surgery
- Where
- 8 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Relation Therapeutics
Acute Promyelocytic Leukemia (APL)
Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
Randomized, Open-Label Study to evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) under Fasting and Fed Conditions, to Compare to IV Arsenic Trioxide
- Trial name
- NCT06882031
- Testing
- Treatment A: Arsenic Trioxide (ATO) Intravenous, Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state, Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state
- Where
- Hong Kong
- Volunteers
- 12 people
- Sponsor
- SDK Therapeutics, Inc.
Acute Myeloid Leukemia
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
The purpose of this study is to determine the safety and effectiveness of pracinostat when combined with azacitadine for patients who are 65 years of age or older and have Acute Myelogenous Leukemia (AML)
- Trial name
- NCT01912274
- Testing
- Pracinostat, Azacitidine
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Helsinn Healthcare SA
Multiple Myeloma
Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma
The study objectives of this study are to determine the effects, safety, and pharmacokinetics of bendamustine for multiple myeloma to a regimen of bendamustine and prednisolone.
- Trial name
- NCT01179490
- Testing
- SyB L-0501, prednisolone
- Where
- 3 sites in Japan
- Volunteers
- 5 people
- Sponsor
- SymBio Pharmaceuticals
Chronic Lymphocytic Leukemia
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose.
- Trial name
- NCT00481091
- Testing
- ABT-263
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 60 people
- Sponsor
- AbbVie
Chronic Kidney Disease; Iron Deficiency Anemia
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA Secondary Objective: To…
- Trial name
- NCT03619850
- Testing
- Ferumoxytol, Iron sucrose
- Where
- 21 sites in United States, Hungary and 3 more
- Volunteers
- 129 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Multiple Myeloma
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
The purpose of this research study is to test the safety and effectiveness of replacing vincristine with a drug called bortezomib (also known as "Velcade"or PS341) in the standard therapy vincristine, doxorubicin (not limited to…
- Trial name
- NCT00441168
- Testing
- adriamycin, bortezomib, dexamethasone
- Where
- 16 sites in Croatia, Germany and 5 more
- Volunteers
- 30 people
- Sponsor
- Janssen-Cilag International NV
Multiple Myeloma
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy.
- Trial name
- NCT00445068
- Testing
- LBH589
- Where
- 29 sites in United States, Germany
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, lenalidomide, and dexamethasone, and to establish the recommended Phase 2 dose for combination treatment to…
- Trial name
- NCT07150091
- Testing
- Belantamab mafodotin, Nirogacestat, Lenalidomide
- Where
- 12 sites in United States, Brazil and 6 more
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.